Histamine pharmacology and new CNS drug targets

CNS Neuroscience and Therapeutics

Volumn 17, Issue 6, 2011, Pages 620-628

  Tiligada, Ekaterini ^a   Kyriakidis, Konstantinos ^a   Chazot, Paul L ^b   Passani, M Beatrice ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b DURHAM UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cognitive impairment; H 3 and H 4 receptors; Histamine; Multiple sclerosis; Neuropathic pain; Neuroprotection; New drug targets; Sleep wake cycle

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; 6 (3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YLOXY) N METHYLNICOTINAMIDE; BF 2 649; CENTRAL NERVOUS SYSTEM AGENTS; GSK 239512; HISTAMINE; HISTAMINE H3 RECEPTOR; HISTAMINE H4 RECEPTOR; JNJ 17216498; MK 0249; NEW DRUG; PF 03654746; PITOLISANT; UNCLASSIFIED DRUG; UR 63325;

ALZHEIMER DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; CATAPLEXY; COGNITIVE DEFECT; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYPERALGESIA; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NARCOLEPSY; NEUROIMMUNOLOGY; NEUROPATHIC PAIN; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SCHIZOPHRENIA; SLEEP WAKING CYCLE; SOMNOLENCE; TRANSLATIONAL RESEARCH;

ANIMALS; BRAIN; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM AGENTS; COGNITION DISORDERS; HISTAMINE; HISTAMINE AGENTS; HUMANS; MULTIPLE SCLEROSIS; NEURALGIA; NEUROPROTECTIVE AGENTS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE; RECEPTORS, HISTAMINE H3; SLEEP DISORDERS;

EID: 82355169156     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00212.x     Document Type: Article

References (68)

1. Moya-Garcia AA, Medina MA, Sánchez-Jiménez F. Mammalian histidine decarboxylase: From structure to function. Bioessays 2005;27:57-63.
2. Dale HH, Laidlaw PP. The physiological action of β-imidazolylethylamine. J Physiol 1910;41:318-341.
3. Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev 2008;88:1183-1241.
4. Kakavas S, Zampeli E, Papamichael K, Delitheos B, Tiligada E. The mast cell pathway to inflammation and homeostasis: Pharmacological insights. Anti-Inflamm Anti-Allergy Agents Med Chem 2006;5:323-334.
5. Prinz C, Zanner R, Gratzl M. Physiology of gastric enterochromaffin-like cells. Annu Rev Physiol 2003;65:371-382.
6. st century renaissance of the basophil? Current insights into its role in allergic responses and innate immunity. Exp Dermatol 2006;15:855-864.
7. 3) of histamine receptor. Nature 1983;302:832-837.
8. Panula P, Yang HY, Costa E. Histamine-containing neurons in the rat hypothalamus. Proc Natl Acad Sci USA 1984;81:2572-2576.
9. Parsons ME, Ganellin CR. Histamine and its receptors. Br J Pharmacol 2006;147(S1):S127-S135.
10. 4 receptor. Br J Pharmacol 2009;157:14-23.
11. 2 receptor knock-out mice. Brain Res Bull 2009;78:189-194.
12. 4 receptors as novel drug targets. Expert Opin Investig Drugs 2009;18:1519-1531.
13. 4 receptor is functionally expressed on neurons in the mammalian CNS. Br J Pharmacol 2009;157:55-63.
14. 4 receptor in immune and inflammatory disorders. Br J Pharmacol 2009;157:24-33.
15. Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 2003;4:121-130.
16. 3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 2004;25:618-625.
17. 3 receptor drugs. Nat Rev Drug Discov 2005;4:107-120.
18. 3 receptor: An attractive target for the treatment of cognitive disorders. Br J Pharmacol 2008;154:1166-1181.
19. Kwiatkowski H. Histamine in nervous tissue. J Physiol 1943;102:32-41.
20. White T. Formation and catabolism of histamine in brain tissue in vitro. J Physiol 1959;149:34-42.
21. 1 receptors of mouse neuroblastoma cells. Nature 1978;274:176-177.
22. Maurer I, Volz HP. Cell-mediated side effects of psychopharmacological treatment. Arzneimittelforschung 2001;51:785-792.
23. Watanabe T, Taguchi Y, Hayashi H, et al. Evidence for the presence of a histaminergic neuron system in the rat brain: An immunohistochemical analysis. Neurosci Lett 1983;39:249-254.
24. 1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 2007;104:3456-3459.
25. Watanabe T, Yamatodani A, Maeyama K, Wada H. Pharmacology of α-fluoromethylhistidine, a specific inhibitor of histidine decarboxylase. Trends Pharmacol Sci 1990;11:363-367.
26. 3 receptor signaling negatively regulates susceptibility to autoimmune inflammatory disease of the CNS. Proc Natl Acad Sci USA 2007;104:10146-10151.
27. Musio S, Gallo B, Scabeni S, et al. A key regulatory role for histamine in experimental autoimmune encephalomyelitis: Disease exacerbation in histidine decarboxylase-deficient mice. J Immunol 2006;176:17-26.
28. Matsumoto I, Inoue Y, Shimada T, Aikawa T. Brain mast cells act as an immune gate to the hypothalamicpituitary-adrenal axis in dogs. J Exp Med 2001;194:71-78.
29. Steinman L. Elaborate interactions between the immune and nervous systems. Nat Immunol 2004;5:575-581.
30. Kakavas S, Tiligada E. Hypothalamic histamine levels in hyperthyroid, arthritic and C48/80-treated rats. Inflamm Res 2005;54(S1):S30-S31.
31. Kakavas S, Tiligada E. Time course of thyroxine on hypothalamic histamine in the rat. Inflamm Res 2006;55(S1):S32-S33.
32. Lambracht-Hall M, Dimitriadou V, Theoharides TC. Migration of mast cells in the developing rat brain. Brain Res 1990;56:151-159.
33. Theoharides TC, Konstantinidou AD. Corticotropin-releasing hormone and the blood-brain-barrier. Front Biosci 2007;12:1615-1628.
34. 3 receptors in rat brain areas. Neuroscience 1993;52:169-189.
35. 3 histamine receptor in the mouse brain. Neuroreport 2001;12:259-262.
36. 3 receptor. Mol Pharmacol 1999;55:1101-1107.
37. 3 receptor. Trends Pharmacol Sci 2007;28:350-357.
38. 4 antibody. Inflamm Res 2009;59(S2):S197-S198.
39. 4 receptors in the central nervous system of human and rat. Brain Res 2009;1250:41-48.
40. 4 receptors. J Physiol 2007;583:731-742.
41. 4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats. Pharmacol Biochem Behav 2010;95:41-50.
42. 4 receptor. Biochem J 2008;414:121-131.
43. Anaclet C, Parmentier R, Ouk K, et al. Orexin/hypocretin and histamine: Distinct roles in the control of wakefulness demonstrated using knock-out mouse models. J Neurosci 2009;29:14423-14438.
44. 1 antagonism: Novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr 2008;13:1027-1038.
45. Barbier AJ, Bradbury MJ. Histaminergic control of sleep-wake cycles: Recent therapeutic advances for sleep and wake disorders. CNS Neurol Disord Drug Targets 2007;6:31-43.
46. -/- mice and patients. Neurobiol Dis 2008;30:74-83.
47. Arnulf I. Results of clinical trials of tiprolisant in narcolepsy and Parkinson's disease. Eur Neuropsychopharmacol 2009;19:S204.
48. 3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 2007;321:1032-1045.
49. 35S]GTPgamma[S] binding in rat striatum: Evidence for additive effects but lack of interactions. Biochem Pharmacol 2007;73:1172-1181.
50. 3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J Pharmacol Exp Ther 2003;305:897-908.
51. 3 receptor antagonist. J Pharmacol Exp Ther 2005;313:176-190.
52. Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev 2006;51:240-264.
53. 3 receptors inhibits formalin-induced inflammation and nociception, respectively. Pharmacol Biochem Behav 2007;88:122-129.
54. 3 receptor antagonists GSK 189254 and GSK 334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain. Pain 2008;138:61-69.
55. Baron R, Schwarz K, Kleinert A, Schattschneider J, Wasner G. Histamine-induced itch converts into pain in neuropathic hyperalgesia. Neuroreport 2001;12:3475-3478.
56. 4 receptors in allergic inflammation: The search for new antihistamines. Nat Rev Drug Discov 2008;7:41-53.
57. 3 receptors. J Pain 2005;6:193-200.
58. Lozada A, Munyao N, Sallmen T, Lintunen M, Leurs R, Lindsberg PJ, Panula P. Postischemic regulation of central histamine receptors. Neuroscience 2005;136:371-379.
59. Kukko-Lukjanov TK, Soini S, Taira T, Michelsen KA, Panula P, Holopainen IE. Histaminergic neurons protect the developing hippocampus from kainic acid-induced neuronal damage in an organotypic coculture system. J Neurosci 2006;26:1088-1097.
60. Lintunen M, Sallmen T, Karlstedt K, Panula P. Transient changes in the limbic histaminergic system after systemic kainic acid-induced seizures. Neurobiol Dis 2005;20:155-169.
61. 3 receptor induces phosphorylation of the Akt/GSK-3 beta pathway in cultured cortical neurons and protects against neurotoxic insults. J Neurochem 2009;110:1469-1478.
62. Kaytor MD, Orr HT. The GSK3 beta signaling cascade and neurodegenerative disease. Curr Opin Neurobiol 2002;12:275-278.
63. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 2008;104:1433-1439.
64. Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol 2010;9:299-308.
65. Linker RA, Lee DH. Models of autoimmune demyelination in the central nervous system: On the way to translational medicine. Exp Transl Stroke Med 2009;1:5.
66. Logothetis L, Mylonas IA, Baloyannis S, et al. A pilot, open label, clinical trial using hydroxyzine in multiple sclerosis. Int J Immunopathol Pharmacol 2005;18:771-778.
67. Pedotti R, DeVoss JJ, Houssef S, Mitchell D, Wedemeyer J, Madanat R. Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. Proc Nat Acad Sci USA 2003;100:1867-1872.
68. 2 receptor knockout mice is due to dysregulation of cytokine production by antigen-presenting cells. Am J Pathol 2004;164:883-892.